The continuation of AREA NS038444, which began in June 1999 and is scheduled to end May 2005, is requested. Significant progress has been made towards the central goal of the program, and this application outlines plans for further hypothesis-driven structure-based drug design studies which use isoxazole chemistry developed in our labs. 1. NMDA and AMPA are sub-types of glutamate receptors which are involved with learning, memory and are affected by aging. We propose to further explore the application of our catalytic asymmetric synthesis [reference 1] to prepare ligands that bind to, and to distinguish between, these GluR subtypes. 2. The Glutamate transporters are important in the glutamate-glutamine cycle, and recent preliminary Structure Activity Relationship (SAR) data from the collaboration between Dr. Richard Bridges (University of Montana) and our lab indicates a distinction between the AMPA glutamate receptor and the system Xc- transporter, which we may be able to exploit using our synthetic methodology to develop binding selectivity. Therefore, the synthesis of ligands to further delineate selectivity between these glutamate binding proteins is proposed. 3. Study of the conformational dynamics of the intact receptor and transporter would be facilitated by access to spectroscopic probes. We propose to prepare molecules to spectroscopically study the glutamate receptor and transporter system Xc-. We have reported very encouraging progress towards the first aim, observed exciting preliminary findings for the second, and present hypothesis-driven, molecular-target-based design towards all of our endeavors. And also relevant to the special considerations for the AREA program, our research group has had a significant positive impact on the participation of University of Idaho students in research. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Academic Research Enhancement Awards (AREA) (R15)
Project #
2R15NS038444-03A1
Application #
7029159
Study Section
Neurotransporters, Receptors, and Calcium Signaling Study Section (NTRC)
Program Officer
Silberberg, Shai D
Project Start
1999-05-01
Project End
2007-06-30
Budget Start
2006-01-04
Budget End
2007-06-30
Support Year
3
Fiscal Year
2006
Total Cost
$67,272
Indirect Cost
Name
University of Idaho
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
075746271
City
Moscow
State
ID
Country
United States
Zip Code
83844
Steiger, Scott A; Li, Chun; Backos, Donald S et al. (2017) Dimeric isoxazolyl-1,4-dihydropyridines have enhanced binding at the multi-drug resistance transporter. Bioorg Med Chem 25:3223-3234
Steiger, Scott A; Li, Chun; Campana, Charles F et al. (2016) Lanthanide and asymmetric catalyzed syntheses of sterically hindered 4-isoxazolyl-1,4-dihydropyridines and 4-isoxazolyl-quinolones. Tetrahedron Lett 57:423-425
Weaver, Matthew J; Kearns, Alison K; Stump, Sascha et al. (2015) AIMing towards improved antitumor efficacy. Bioorg Med Chem Lett 25:1765-1770
Szabon-Watola, Monika I; Ulatowski, Sarah V; George, Kathleen M et al. (2014) Fluorescent probes of the isoxazole-dihydropyridine scaffold: MDR-1 binding and homology model. Bioorg Med Chem Lett 24:117-21
Matti, Afnan A; Mirzaei, Joseph; Rudolph, John et al. (2013) Microwave accelerated synthesis of isoxazole hydrazide inhibitors of the system xc- transporter: Initial homology model. Bioorg Med Chem Lett 23:5931-5
Mirzaei, Yousef R; Weaver, Matthew J; Steiger, Scott A et al. (2012) Improved synthesis of 3-aryl isoxazoles containing fused aromatic rings. Tetrahedron 68:10360-10364
Hulubei, Victoria; Meikrantz, Scott B; Quincy, David A et al. (2012) 4-Isoxazolyl-1,4-dihydropyridines exhibit binding at the multidrug-resistance transporter. Bioorg Med Chem 20:6613-20
Patel, Sarjubhai A; Rajale, Trideep; O'Brien, Erin et al. (2010) Isoxazole analogues bind the system xc- transporter: structure-activity relationship and pharmacophore model. Bioorg Med Chem 18:202-13
Gajewski, Mariusz P; Beall, Howard; Schnieder, Mark et al. (2009) Bis-anthracenyl isoxazolyl amides have enhanced anticancer activity. Bioorg Med Chem Lett 19:4067-9
Han, Xiaochun; Li, Chun; Mosher, Michael D et al. (2009) Design, synthesis and biological evaluation of a novel class of anticancer agents: anthracenylisoxazole lexitropsin conjugates. Bioorg Med Chem 17:1671-80

Showing the most recent 10 out of 15 publications